Affiliation:
1. National Research Center for Hematology, Ministry of Health of Russia
Abstract
Invasive aspergillosis is the leading fungal infection in patients with hematological malignancies. The review represents the incidence of invasive aspergillosis in different groups of patients, risk factors for its development, treatment options, including the new drug isavuconazole.
Publisher
Publishing House ABV Press
Reference39 articles.
1. Herbrecht R., Bories P., Moulin J. et al. Risk stratification for invasive aspergillosis. Ann N Y Acad Sci 2012;1272:23–30. DOI: 10.1111/j.17496632.2012.06829.x.
2. Pomares H., Arnan M., SánchezOrtega I. et al. Invasive fungal infections in AML/ MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis? Mycoses 2016;59(8):516–9. DOI: 10.1111/myc.12500.
3. Falantes J.F., Calderón C., MárquezMalaver F.J. et al. Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis. Clin Lymphoma Myeloma Leuk 2014;14(1):80–6. DOI: 10.1016/j.clml.2013.09.014.
4. Klyasova G.A., Okhmat V.A., Vasilyeva V.A. et al. Invasive mycoses in patients with acute leukemia and in recipients of hematopoietic stem cells. Results of a multicenter prospective observational study in Russia (RIFI). Gematologiya i transfuziologiya = Hematology and Transfusiology 2016;61(1–S1):19. (In Russ.).
5. Popova M.O., Zubarovskaya L.S., Klimko N.N. et al. Invasive mycoses in recipients of allogeneic hematopoietic stem cell. Terapevticheskiy arkhiv = Therapeutic Archive 2012;84(7):50–7. (In Russ.).